Antitumour evaluation of a ribonuclease resistant double-stranded RNA-polyquaternary ammonium complex (BRL 10739).
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002277:Carcinoma / Q000188:drug therapy*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008214:Lymphocytes / Q000187:drug effects; D008223:Lymphoma / Q000188:drug therapy*; D051379:Mice; D008811:Mice, Inbred DBA; D009362:Neoplasm Metastasis; D009374:Neoplasms, Experimental / Q000188:drug therapy; D010179:Pancreas / Q000201:enzymology; D011073:Polyamines / Q000627:therapeutic use; D000644:Quaternary Ammonium Compounds / Q000627:therapeutic use*; D012313:RNA / Q000633:toxicity; D012330:RNA, Double-Stranded; D012367:RNA, Viral / Q000627:therapeutic use*; D012260:Ribonucleases; D013329:Structure-Activity Relationship; D013921:Thrombocytopenia / Q000139:chemically induced
D011073:Polyamines; D000644:Quaternary Ammonium Compounds; D012330:RNA, Double-Stranded; D012367:RNA, Viral; C006243:BRL 10739; D012313:RNA; D012260:Ribonucleases